FDA Grants Priority Review To Cladribine Tablets For The Treatment Of Relapsing Forms Of MS

FDA Grants Priority Review To Cladribine Tablets For The Treatment Of Relapsing Forms Of MS
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation by the FDA, which means the review period for the NDA is reduced. The …

Read more on Medical News Today